Cytospire Theraputes Limited is a limited liability company (Ltd) established in 2023, operating from its headquarters at 3rd Floor 1 Ashley Road, Altrincham, WA14 2DT. The company’s registration number is 14688240 and is currently active. Cytospire specializes in the research, development, and commercialization of innovative therapies focused on the treatment of neurological disorders. The core of Cytospire’s business lies in its proprietary technology platform, primarily centered around its novel drug delivery system, designed to enhance the efficacy and safety of therapeutic interventions. Their research efforts concentrate on developing treatments for conditions including Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative illnesses. Cytospire’s activities encompass a range of preclinical and clinical trials, with a significant emphasis on optimizing drug delivery mechanisms. The company’s strategic focus is on identifying and validating novel therapeutic targets, ultimately aiming to improve patient outcomes and quality of life. Cytospire’s international presence is currently limited, primarily focused on research collaborations and strategic partnerships. The company employs a skilled workforce, currently rated as a Worker (A rating) and is seeking to attract additional talent. The company’s SIC codes include: - 72110: Research and experimental development on biotechnology. Further details regarding the company’s valuation, funding, and investors are available upon request.

Cytospire Theraputes Limited is a limited liability company (Ltd) established in 2023, operating from its headquarters at 3rd Floor 1 Ashley Road, Altrincham, WA14 2DT. The company’s registration number is 14688240 and is currently active. Cytospire specializes in the research, development, and commercialization of innovative therapies focused on the treatment of neurological disorders. The core of Cytospire’s business lies in its proprietary technology platform, primarily centered around its novel drug delivery system, designed to enhance the efficacy and safety of therapeutic interventions. Their research efforts concentrate on developing treatments for conditions including Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative illnesses. Cytospire’s activities encompass a range of preclinical and clinical trials, with a significant emphasis on optimizing drug delivery mechanisms. The company’s strategic focus is on identifying and validating novel therapeutic targets, ultimately aiming to improve patient outcomes and quality of life. Cytospire’s international presence is currently limited, primarily focused on research collaborations and strategic partnerships. The company employs a skilled workforce, currently rated as a Worker (A rating) and is seeking to attract additional talent. The company’s SIC codes include: - 72110: Research and experimental development on biotechnology. Further details regarding the company’s valuation, funding, and investors are available upon request.